148081-72-5
148081-72-5 結(jié)構(gòu)式
基本信息
己氧基三甲基苯酚
4-己氧基-2,3,6-三甲基苯酚
HX-1171
4-hexoxy-2
1-O-Hexyl-2
HX-1171(HTHQ)
HTHQ(HX-1171)
6-trimethylphenol
5-trimethylhydroquinone
HEXYLOXY TRIMETHYLPHENOL
4-hexoxy-2,3,6-trimethylphenol
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | H1741 | 4-(己氧基)-2,3,6-三甲基苯酚 4-(Hexyloxy)-2,3,6-trimethylphenol | 148081-72-5 | 50mg | 210元 |
| 2024/11/08 | H1741 | 4-(己氧基)-2,3,6-三甲基苯酚 4-(Hexyloxy)-2,3,6-trimethylphenol | 148081-72-5 | 250mg | 990元 |
| 2024/11/08 | S5314 | CS-2408 HTHQ (1-O-Hexyl-2,3,5-trimethylhydroquinone) | 148081-72-5 | 25mg | 795.38元 |
常見問題列表
ROS
HTHQ (0-100 μM; 24 hours; PC12 cells) treatment increases cell viabilities in a dose-dependent manner.
HTHQ (10 μM; 0.6-24 hours; PC12 cells) inhibits 3,4-L-Dihydroxyphenylalanine (L-DOPA) -induced phosphorylation of sustaines extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). HTHQ also normalizes L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression, promoting cell survival.
Cell Viability Assay
| Cell Line: | PC12 cells |
| Concentration: | 0 μM, 1 μM, 10 μM, and 100 μM |
| Incubation Time: | 24 hours |
| Result: | Reduced cell viability at 24 hours caused by both 100 and 200 μM L-DOPA was significantly attenuated. |
Western Blot Analysis
| Cell Line: | PC12 cells |
| Concentration: | 10 μM |
| Incubation Time: | 0.6-24 hours |
| Result: | Inhibited L-DOPA-induced phosphorylation of sustained extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). And also normalized L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression. |
HTHQ (50-200 mg/kg; oral administration; for 4 weeks; specific pathogen-free male Sprague Dawley rats) treatment significantly improves liver weight and serum chemistry level. HTHQ reduces hydroxyproline and malondialdehyde level in the liver. HTHQ treatment also reduces fibrotic septa. HTHQ administration shows reduced mRNA level of PDGF (Plateletderived growth factor) , α-SMA (α-smooth muscle actin) and TGF-β (transforming growth factor-β) than DMN-induced hepetic fibrosis animals in the liver tissue.
| Animal Model: | 48 specific pathogen-free male Sprague Dawley (SD) rats (6-week-old ) with dimethylnitrosamine (DMN) |
| Dosage: | 50 mg/kg, 100 mg/kg, 200 mg/kg |
| Administration: | Oral administration; for 4 weeks |
| Result: | Improved against DMN-induced liver fibrosis in male SD rats. |